Evidence Level
Sulbutiamine is a synthetic derivative of vitamin B1 developed in Japan and later used clinically in France as Arcalion for treating asthenia. Preclinical research highlights its superior blood-brain barrier (BBB) penetration, dopaminergic modulation, and cholinergic potentiation (Micheau et al., 1985). Chronic administration in mice improved long-term memory retention, associated with a 10% increase in hippocampal choline uptake (Micheau et al., 1985).
Clinical evidence is primarily from small trials and post-marketing surveillance. A randomized controlled trial involving 20 patients with psychogenic erectile dysfunction showed sulbutiamine significantly improved erectile function, as indicated by an increase in IIEF scores from 17.5 to 24.8 (Dmitriev et al., 2005). However, a double-blind study with 326 patients investigating its effects on chronic postinfectious fatigue found no significant differences between sulbutiamine doses and placebo, though women reported less fatigue at day 7 (P < 0.01) (Tiev et al., 1999).
A recent review by Starling-Soares et al. (2020) underscores sulbutiamine's potential health applications, including anti-fatigue, nootropic, antioxidant effects, and treatment for infections and cancer. However, the authors stress the need for further randomized controlled trials to validate these findings. The nootropic community values sulbutiamine primarily for its ability to enhance motivation via dopamine receptor upregulation.